Payment overview · 2025
General Payments
$2,938.24
160 reported records · 35 companies
Healthcare provider profile · identity verified
Ghazwan Atto, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WYANDOTTE, MI · NPI 1578553301
Verified facts
What the public records show
CMS Open Payments records show Ghazwan Atto, M.D. received $2,938.24 in general payments during 2025 across 160 reported records.
Novo Nordisk Inc accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 57 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Korlym, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Wegovy, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 247 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Korlym by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 353 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 386 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 276 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 353 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $494.56 | 16.8% | 30 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $238.41 | 8.1% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$225.74 | 7.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $184.63 | 6.3% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $174.06 | 5.9% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $159.47 | 5.4% | 11 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $153.85 | 5.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $139.50 | 4.8% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $96.34 | 3.3% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $94.17 | 3.2% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $91.62 | 3.1% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $88.92 | 3.0% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $86.57 | 3.0% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $84.25 | 2.9% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $62.45 | 2.1% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $60.84 | 2.1% | 3 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $54.76 | 1.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.39 | 1.5% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $45.31 | 1.5% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $38.78 | 1.3% | 2 | 2025 |
| Krystal Biotech Inc | Unresolved — no canonical attribution shown | $37.38 | 1.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.85 | 1.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.32 | 1.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $30.41 | 1.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.40 | 0.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $24.66 | 0.8% | 1 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $21.03 | 0.7% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $17.68 | 0.6% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $17.38 | 0.6% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $15.21 | 0.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.16 | 0.5% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.71 | 0.5% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $13.98 | 0.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.95 | 0.4% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $3.50 | 0.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,920.86 | 159 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $333.94 | 19 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $306.92 | 18 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $192.88 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $172.36 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $159.47 | 11 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $153.85 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $151.83 | 16 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $143.71 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $121.74 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $118.78 | 8 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $94.17 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $93.89 | 11 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $91.62 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $84.25 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $75.67 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $75.67 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $72.34 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $72.34 | 7 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $67.20 | 3 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $54.76 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.48 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.70 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $48.30 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $46.83 | 3 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $45.93 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $45.39 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $45.31 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $44.77 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $38.78 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $38.78 | 2 | 2025 |
Source payment records
|
|||||
| VYJUVEK Normalized: vyjuvek |
Drug | Krystal Biotech Inc | $37.38 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $36.93 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.32 | 2 | 2025 |
Source payment records
|
|||||
| INPEN SMART INSULIN DELIVERY SYSTEM Normalized: inpen smart insulin delivery system |
Device | Medtronic, Inc. | $32.86 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $32.80 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $32.80 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $32.80 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $31.18 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $30.41 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Sage Therapeutics, LLC | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.95 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $3.50 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $2.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 353 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 44 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 386 | exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 205 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 276 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 164 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
247 | 78 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
353 | 110 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
164 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
386 | 113 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
205 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
131 | 28 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
276 | 82 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
353 | 110 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
44 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1112 | 392 |
| Levothyroxine Sodium | Levothyroxine Sodium | 974 | 291 |
| Losartan Potassium | Losartan Potassium | 750 | 250 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 698 | 259 |
| Metoprolol Succinate | Metoprolol Succinate | 695 | 232 |
| Pantoprazole Sodium | Pantoprazole Sodium | 651 | 236 |
| Omeprazole | Omeprazole | 631 | 207 |
| Gabapentin | Gabapentin | 449 | 118 |
| Metoprolol Tartrate | Metoprolol Tartrate | 401 | 165 |
| Jardiance | Empagliflozin | 386 | 113 |
| Spironolactone | Spironolactone | 377 | 138 |
| Furosemide | Furosemide | 373 | 151 |
| Eliquis | Apixaban | 353 | 110 |
| Clopidogrel | Clopidogrel Bisulfate | 347 | 119 |
| Lisinopril | Lisinopril | 324 | 123 |
| Metformin Hcl | Metformin Hcl | 317 | 113 |
| Duloxetine Hcl | Duloxetine Hcl | 300 | 106 |
| Sertraline Hcl | Sertraline Hcl | 292 | 105 |
| Ozempic | Semaglutide | 276 | 82 |
| Alprazolam | Alprazolam | 270 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 258 | 102 |
| Farxiga | Dapagliflozin Propanediol | 247 | 78 |
| Fluticasone Propionate | Fluticasone Propionate | 232 | 120 |
| Simvastatin | Simvastatin | 232 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 226 | 91 |
| Montelukast Sodium | Montelukast Sodium | 217 | 76 |
| Metformin Hcl Er | Metformin Hcl | 215 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 212 | 79 |
| Carvedilol | Carvedilol | 207 | 66 |
| Mounjaro | Tirzepatide | 205 | 54 |
| Tramadol Hcl | Tramadol Hcl | 201 | 66 |
| Trazodone Hcl | Trazodone Hcl | 193 | 80 |
| Allopurinol | Allopurinol | 188 | 71 |
| Finasteride | Finasteride | 188 | 62 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 164 | 51 |
| Pregabalin | Pregabalin | 161 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 158 | 63 |
| Xarelto | Rivaroxaban | 157 | 45 |
| Entresto | Sacubitril/Valsartan | 156 | 58 |
| Clonazepam | Clonazepam | 154 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 139 | 47 |
| Famotidine | Famotidine | 138 | 60 |
| Doxycycline Hyclate | Doxycycline Hyclate | 137 | 109 |
| Potassium Chloride | Potassium Chloride | 137 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 52 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 131 | 37 |
| Methylprednisolone | Methylprednisolone | 131 | 108 |
| Trulicity | Dulaglutide | 131 | 28 |
| Meloxicam | Meloxicam | 129 | 62 |
| Tizanidine Hcl | Tizanidine Hcl | 127 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 116 | 39 |
| Valsartan | Valsartan | 115 | 37 |
| Prednisone | Prednisone | 106 | 57 |
| Diazepam | Diazepam | 103 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 98 | 43 |
| Buprenorphine | Buprenorphine | 98 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 96 | 32 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 96 | 34 |
| Atenolol | Atenolol | 95 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 43 |
| Buspirone Hcl | Buspirone Hcl | 91 | 25 |
| Bumetanide | Bumetanide | 87 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 87 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 37 |
| Mirtazapine | Mirtazapine | 83 | 32 |
| Baclofen | Baclofen | 81 | 22 |
| Levetiracetam | Levetiracetam | 79 | 19 |
| Nystatin | Nystatin | 79 | 47 |
| Colestipol Hcl | Colestipol Hcl | 78 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | 30 |
| Lamotrigine | Lamotrigine | 77 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 77 | 26 |
| Ezetimibe | Ezetimibe | 76 | 34 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | 27 |
| Methotrexate | Methotrexate Sodium | 73 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 64 |
| Donepezil Hcl | Donepezil Hcl | 71 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 23 |
| Nortriptyline Hcl | Nortriptyline Hcl | 70 | 28 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 63 | 44 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 63 | 32 |
| Azelastine Hcl | Azelastine Hcl | 62 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 61 | 16 |
| Celecoxib | Celecoxib | 59 | 24 |
| Synthroid | Levothyroxine Sodium | 59 | 14 |
| Colchicine | Colchicine | 58 | 27 |
| Fluconazole | Fluconazole | 58 | 43 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 58 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 16 |
| Lorazepam | Lorazepam | 53 | 21 |
| Ibuprofen | Ibuprofen | 52 | 33 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 21 |
| Myrbetriq | Mirabegron | 49 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 16 |
| Alendronate Sodium | Alendronate Sodium | 48 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 31 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | suppressed |
| Nitroglycerin | Nitroglycerin | 46 | 31 |
| Propranolol Hcl | Propranolol Hcl | 46 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 13 |
| Gemtesa | Vibegron | 44 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | 19 |
| Ammonium Lactate | Ammonium Lactate | 43 | 27 |
| Midodrine Hcl | Midodrine Hcl | 43 | 14 |
| Naproxen | Naproxen | 43 | 22 |
| Terazosin Hcl | Terazosin Hcl | 43 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 14 |
| Spiriva Respimat | Tiotropium Bromide | 41 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | suppressed |
| Methocarbamol | Methocarbamol | 39 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 38 | 18 |
| Nifedipine Er | Nifedipine | 38 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 23 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Metolazone | Metolazone | 36 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 15 |
| Warfarin Sodium | Warfarin Sodium | 36 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 28 |
| Repatha Syringe | Evolocumab | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | 20 |
| Hydrocortisone | Hydrocortisone | 33 | 18 |
| Rexulti | Brexpiprazole | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | 15 |
| Folic Acid | Folic Acid | 31 | 13 |
| Lidocaine | Lidocaine | 31 | suppressed |
| Sulfasalazine | Sulfasalazine | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 29 |
| Megestrol Acetate | Megestrol Acetate | 30 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | 12 |
| Primidone | Primidone | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 29 | 23 |
| Nyamyc | Nystatin | 28 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | 11 |
| Sucralfate | Sucralfate | 28 | 14 |
| Torsemide | Torsemide | 28 | 11 |
| Valacyclovir | Valacyclovir Hcl | 28 | 17 |
| Novolog Flexpen | Insulin Aspart | 27 | 16 |
| Repatha Sureclick | Evolocumab | 27 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 16 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Aripiprazole | Aripiprazole | 26 | 13 |
| Linzess | Linaclotide | 26 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | 14 |
| Brilinta | Ticagrelor | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | 11 |
| Enbrel Sureclick | Etanercept | 25 | suppressed |
| Eplerenone | Eplerenone | 25 | 11 |
| Ciclopirox | Ciclopirox | 24 | 14 |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 20 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 14 |
| Prasugrel Hcl | Prasugrel Hcl | 21 | suppressed |
| Xifaxan | Rifaximin | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Epinephrine | Epinephrine | 20 | suppressed |
| Mirabegron Er | Mirabegron | 20 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Risperidone | Risperidone | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Cartia Xt | Diltiazem Hcl | 18 | suppressed |
| Leflunomide | Leflunomide | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Prolia | Denosumab | 18 | 12 |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | 13 |
| Novolog | Insulin Aspart | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 13 |
| Naloxone Hcl | Naloxone Hcl | 16 | 15 |
| Trulance | Plecanatide | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Belbuca | Buprenorphine Hcl | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | 11 |
| Digoxin | Digoxin | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Benzonatate | Benzonatate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 13 | 12 |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Korlym | Mifepristone | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,938.24 · 160 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, ARISTADA, AUSTEDO XR, Auvelity, BREZTRI, Brinsupri, CAPLYTA, CAPVAXIVE, COMIRNATY, CONTRAVE, CREON, Dexcom G6 Transmitter, ELIQUIS, Fluad, Flucelvax, GARDASIL 9, GEMTESA, GIVLAARI, GVOKE HYPOPEN, INPEN SMART INSULIN DELIVERY SYSTEM, JARDIANCE, KISUNLA, KRYSTEXXA, Kerendia, Korlym, LINZESS, LYBALVI, MINIMED 780G, MOUNJARO, NURTEC ODT, Nayzilam, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, Sunosi, Symbravo, TRELEGY ELLIPTA, Tyvaso, UBRELVY, VERQUVO, VIBERZI, VOQUEZNA, VOWST, VRAYLAR, VYJUVEK, Veozah, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZENPEP, ZEPBOUND, ZURZUVAE | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error